Comparison of patient characteristics and details of drug treatment received by CLL-4 patients genotyped and those excluded from study
| . | CLL-4 patients genotyped (N = 425), no. (%) . | CLL-4 patients excluded (N = 352), no. (%) . | P* . |
|---|---|---|---|
| Sex | |||
| Male | 312 (73.4) | 261 (74.1) | — |
| Female | 113 (26.6) | 91 (25.9) | .8 |
| Age | |||
| Less than 60 y | 127 (29.9) | 127 (36.1) | — |
| 60 to 69 y | 168 (39.5) | 121 (34.4) | — |
| Over 70 y | 130 (30.6) | 104 (29.5) | .2 |
| Stage | |||
| A | 104 (24.5) | 87 (24.7) | — |
| B | 186 (43.8) | 166 (47.2) | — |
| C | 135 (31.8) | 99 (28.1) | .5 |
| Died | |||
| Yes | 114 (26.8) | 88 (25.0) | — |
| No | 311 (73.2) | 264 (75.0) | .6 |
| Treatment | |||
| Chlorambucil | 206 (48.5) | 181 (51.4) | — |
| Fludarabine | 112 (26.4) | 82 (23.3) | — |
| Fludarabine and cyclophosphamide | 107 (25.2) | 89 (25.3) | .6 |
| . | CLL-4 patients genotyped (N = 425), no. (%) . | CLL-4 patients excluded (N = 352), no. (%) . | P* . |
|---|---|---|---|
| Sex | |||
| Male | 312 (73.4) | 261 (74.1) | — |
| Female | 113 (26.6) | 91 (25.9) | .8 |
| Age | |||
| Less than 60 y | 127 (29.9) | 127 (36.1) | — |
| 60 to 69 y | 168 (39.5) | 121 (34.4) | — |
| Over 70 y | 130 (30.6) | 104 (29.5) | .2 |
| Stage | |||
| A | 104 (24.5) | 87 (24.7) | — |
| B | 186 (43.8) | 166 (47.2) | — |
| C | 135 (31.8) | 99 (28.1) | .5 |
| Died | |||
| Yes | 114 (26.8) | 88 (25.0) | — |
| No | 311 (73.2) | 264 (75.0) | .6 |
| Treatment | |||
| Chlorambucil | 206 (48.5) | 181 (51.4) | — |
| Fludarabine | 112 (26.4) | 82 (23.3) | — |
| Fludarabine and cyclophosphamide | 107 (25.2) | 89 (25.3) | .6 |
—indicates not applicable.
Chi-square test.